Manning & Napier Overseas Series Class S
MNOSX
NASDAQ- -
USD
- -
- -
- -
- -
(- -)
Recent
price
- -
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Manning & Napier Overseas Series Class S (MNOSX) is a mutual fund series of Manning & Napier Fund, Inc. that seeks to maximize long-term growth by investing principally in common stocks of non-U.S. companies domiciled in developed and emerging markets worldwide; it normally allocates at least 80% of assets to foreign equity securities, including American Depositary Receipts, with country limits capped at the higher of 15% or double the MSCI EAFE Index weighting and emerging markets exposure limited to 35% at purchase. The fund emphasizes a bottom-up stock selection process targeting high-quality growth and value opportunities across sectors such as information technology, industrials, financials, and consumer discretionary, with top holdings including Taiwan Semiconductor Manufacturing, Tencent Holdings, AstraZeneca, and Deutsche Boerse; it maintains a portfolio of approximately 36 stocks, active share of 90%, and annual turnover around 57%. Managed by Manning & Napier Advisors, LLC since the broader Overseas Series inception in 1998 (Class S launched September 21, 2018), the fund features a net expense ratio of 1.06% (including a 0.25% 12b-1 fee), $2,000 minimum investment (waivable for certain plans), and assets under management of about $352 million as of September 2025. Headquartered in Fairport, New York, Manning & Napier Advisors, LLC—the fund's investment adviser founded in 1970—provides a range of U.S. and international equity, fixed income, and multi-asset strategies to high-net-worth individuals, institutions, pension plans, and retirement accounts primarily in the United States. In recent developments, the fund received a one-time payment in Q3 2020 unrelated to current holdings, boosting 2020 year-to-date performance by approximately 3.6%; portfolio managers adjusted positions in Q3 2025 by adding GlaxoSmithKline, increasing Taiwan Semiconductor exposure, exiting railroad holdings, and selling Infineon Technologies amid ongoing economic sensitivity positioning.